Articles by A. W. Bleyer, MD
Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphomas
ByAndreas H. Sarris, MD, PhD,Alexandria T. Phan, MD,A. Goy, MD,Jorge Romaguera, MD,Fredrick B. Hagemeister, MD,Maria A. Rodriguez, MD,Peter Mclaughlin, MD,Barbara Pro, MD,L. Jeffrey Medeiros, MD,Barry Samuels, MD,Ofie Mesina, RN,A. W. Bleyer, MD,Fernando Cabanillas, MD Because irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity, we investigated its activity in relapsed or refractory non-Hodgkin’s lymphomas (NHLs). Irinotecan at 300 mg/m² IV was administered every 21 days with intensive loperamide management of diarrhea.
